Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 3 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.

DPP-4 inhibitors may up risk of bullous pemphigoid

15 Sep 2020

Use of dipeptidyl-peptidase 4 (DPP-4) inhibitors is linked to the development of bullous pemphigoid, although the risk increase appears to be limited to linagliptin, according to the results of a meta-analysis.

Researchers conducted a systematic review of studies evaluating the effect of exposure to DPP-4 inhibitor (eg, sitagliptin, vildagliptin, omarigliptin, saxagliptin, alogliptin, trelagliptin, anagliptin, linagliptin, gemigliptin, evogliptin, or teneligliptin) vs placebo in relation to the risk of the autoimmune pruritic skin disease. All trials lasted ≥24 weeks and involved type 2 diabetes patients.

A total of 138 studies, involving 61,514 patients on DPP-4 inhibitors and 59,661 patients on placebo, were eligible for inclusion in the meta-analysis. However, only six studies reported at least one event of pemphigoid (17 cases in the active treatment group and one in the control group).

Of the 17 cases of pemphigoid with DPP-4 inhibitors, 14 were with linagliptin, two with saxagliptin, and one with sitagliptin.

Pooled data, obtained using the Mantel-Haenszel (MH) method, showed that DPP-4 inhibitors were associated with an increased risk of pemphigoid (odds ratio [OR], 4.44, 95 percent confidence interval [CI], 1.31–15.00; p=0.020), with no evidence of heterogeneity (I2, 0 percent). The estimate obtained using a fixed-effect model was consistent (OR, 5.57, 95 percent CI, 1.78–17.40).

In a separate analysis of linagliptin trials, the drug was likewise associated with a significant increase in pemphigoid risk (OR, 4.69, 95 percent CI, 1.09–20.22; p=0.04).

Visual analysis of the funnel plot revealed no publication bias.

Editor's Recommendations
Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 3 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.